Cathflo buyout

Intravenous products: Roche has announced that it is commencing a cash tender offer for all outstanding publicly-held shares of Genentech for US$86.50 per share.

Genentech are the manufacturers of Cathflo® Activase® (Alteplase) which is indicated for the restoration of function to central venous access devices (CVADs) as assessed by the ability to withdraw blood.

Click here for the full news story.

More IV news at IVTEAM

Other stories

• Needlestick in a general hospital
• Canadian CLABSI rates published
• MRSA and peripheral IV
• Chlorhexidine antisepsis
• Retrieval of PICC fragment
• Pre CVC insertion skin prep
• Needlestick injury survey
• Hand hygiene guidelines revised
• Patient experience video
• Medication error prevention
• Intravenous (IV) therapy competencies
• Improving peripheral IV cannula care

Add IVTEAM to Technorati Favorites